Use in patients with resistant and relapsing Multiple Myeloma. A Phase II Study
| Autor: | R. B. Pollard, Howard Ozer, John J. Costanzi, R. J. Spiegel, M. R. Cooper, J. H. Scarffe, R. W. Ferraresi |
|---|---|
| Rok vydání: | 1985 |
| Předmět: |
medicine.medical_specialty
Performance status Cyclophosphamide business.industry Phases of clinical research Combination chemotherapy medicine.disease Gastroenterology Surgery Refractory Internal medicine Plasma Cell Myeloma medicine medicine.symptom business Bone pain Multiple myeloma medicine.drug |
| Zdroj: | Interferon Alpha-2: Pre-Clinical and Clinical Evaluation ISBN: 9781461296188 |
| DOI: | 10.1007/978-1-4613-2579-6_8 |
| Popis: | The use of phenylalanine mustard or cyclophosphamide alone and in various combination chemotherapy programs has improved the response rate and disease-free survival in multiple myeloma. However, once those patients have become refractory or have relapsed on that therapy, subsequent salvage treatment has been very disappointing. Between 1979 and 1982 a number of preliminary studies were reported using human leukocyte interferon (Cantell) in patients with refractory or relapsing myeloma. The total number of patients reported in those studies was 25. Five of these patients had a partial response. Therefore, the present study utilizing Schering human alpha-2 interferon, was undertaken in a multi-institutional program. Thirty-eight fully evaluable patients were treated with three different alpha-2 interferon schedules. Seven of these patients had a response with one a complete remission. Of the seven responders, two were from 19 refractory patients and five from 19 relapsing patients. The complete response continues in maintained remission at 72+ weeks with the other responders lasting from 12 to 58+ weeks. In most of these patients an improvement in performance status and bone pain was noted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|